SCHEMBL826368

SCHEMBL826368

CC(C)Oc1ccccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.44
LMNA P02545 3/20 0.44
POLB P06746 2/20 0.44
CCR1 P32246 2/20 0.44
CCR5 P51681 2/20 0.44
CCR8 P51685 2/20 0.44
CYP1A2 P05177 2/20 0.44
METAP1 P53582 1/20 0.44
BLM P54132 1/20 0.44
HIF1A Q16665 1/20 0.44
DOHH Q9BU89 1/20 0.44
P4HTM Q9NXG6 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29388428 1.00 KDM4E (0.44) KDM4ELMNAPOLBCCR1CCR5
Formaldehyde SCHEMBL28133646 0.94 ALDH1A1 (0.40) KDM4ELMNAPOLBCCR1CCR5
SCHEMBL3645535 0.86 KDM4E (0.44) KDM4ELMNAPOLBCCR1CCR5
Triethylene Glycol SCHEMBL17421661 0.83 SMN1; SMN2 (0.37) KDM4ELMNAPOLBTRPM8SMN1; SMN2
SCHEMBL23701489 0.83 KDM4E (0.41) KDM4ELMNAPOLBCCR1CCR5
SCHEMBL20995459 0.83 KDM4E (0.41) KDM4ELMNAPOLBCCR1CCR5
SCHEMBL2307870 0.83 KDM4E (0.41) KDM4ELMNAPOLBCCR1CCR5
SCHEMBL4632146 0.83 KDM4E (0.41) KDM4ELMNAPOLBCCR1CCR5
SCHEMBL5281969 0.83 SMN1; SMN2 (0.41) KDM4ELMNAPOLBCCR1CCR5
SCHEMBL11001241 0.83 SMN1; SMN2 (0.41) KDM4ELMNAPOLBCCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113979928-B Preparation method of 2-chloro-5-nitropyridine 蚌埠中实化学技术有限公司 2023-09-05 CN claimed
CN-113979928-A Preparation method of 2-chloro-5-nitropyridine 蚌埠中实化学技术有限公司 2022-01-28 CN claimed
EP-2496628-A1 METHOD FOR PRODUCING AN AQUEOUS POLYMER DISPERSION BASF SE (DE) 2012-09-12 EP claimed
US-20120208959-A1 METHOD FOR PRODUCING AN AQUEOUS POLYMER DISPERSION BASF SE (DE) 2012-08-16 US claimed
WO-2012076426-A1 METHOD FOR PRODUCING AN AQUEOUS POLYMER PRODUCT DISPERSION BASF SE (DE) 2012-06-14 WO claimed
US-20120149840-A1 PROCESS FOR PRODUCING AN AQUEOUS POLYMER DISPERSION Univ. of Southern Mississippi Res. Foundation (US) 2012-06-14 US claimed
WO-2011051374-A1 METHOD FOR PRODUCING AN AQUEOUS POLYMER DISPERSION BASF SE (DE) 2011-05-05 WO claimed
US-12617769-B2 Chemical compound as thyroid hormone beta receptor agonist and use thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2026-05-05 US disclosed
US-12552748-B2 Pyridine (thio)amides as fungicidal compounds BAYER AKTIENGESELLSCHAFT (DE) 2026-02-17 US disclosed
EP-4318630-B1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY ASAHI CHEMICAL IND (JP) 2025-10-22 EP disclosed
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte ASAHI KASEI KABUSHIKI KAISHA (JP) 2025-01-14 US disclosed
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 US disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 US disclosed
US-6200975-B1 FOR COGNITION ENHANCEMENT THERAPY MERCK SHARP & DOHME LIMITED (GB) 2001-03-13 US disclosed
EP-0986562-A1 SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS MERCK SHARP & DOHME LTD. (GB) 2000-03-22 EP disclosed
EP-0977743-A1 PROTEASE INHIBITORS Smithkline Beecham (US) 2000-02-09 EP disclosed
WO-1998050385-A1 SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1998-11-12 WO disclosed
WO-1998049152-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-05 WO disclosed
CN-1036570-A The new silylation sulfide of new alkyl sulfur compounds of azepine and azepine, they the preparation method, contain their preparation and they are as the application of sterilant HOECHST AG (DE) 1989-10-25 CN disclosed
CN-87100628-A The production method of silicoorganic compound and make the sterilant and the miticide of activeconstituents with it 1988-03-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 KDM4E 3978/4885LMNA 4020/4885POLB 4152/4885
US-20120149840-A1 PROCESS FOR PRODUCING AN AQUEOUS POLYMER DISPERSION PUF60, PARG, ACMSD KDM4E 4038/4885LMNA 2901/4885POLB 201/4885
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK KDM4E 2009/4885LMNA 4345/4885POLB 1119/4885
US-12199280-B2 Non-aqueous secondary battery and non-aqueous electrolyte CLK2, TYK2, CLK3 KDM4E 1884/4885LMNA 248/4885POLB 182/4885
US-12617769-B2 Chemical compound as thyroid hormone beta receptor agonist and use thereof THRB, TSHR, THRA KDM4E 3890/4885LMNA 1606/4885POLB 3048/4885
US-12552748-B2 Pyridine (thio)amides as fungicidal compounds CBR1, CBR3, TH KDM4E 1771/4885LMNA 3748/4885POLB 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.